Human Pharma

Human Pharma is our prescription medicine unit which focuses on various therapeutic areas. Through its Diabetes, Oncology, Cardiovascular and Respiratory portfolios, Boehringer Ingelheim MENA aims to bring solutions to its patients that will improve their quality of life. Stroke prevention and treatment is one of our main focus areas in the region, where we aim at enhancing stroke management, raising awareness hoping at saving lives through innovative solutions.

Our patients are at the core of our focus and we are committed to providing positive impact to people’s lives.  Boehringer Ingelheim leads by value through innovation, and caring for patients, and customers.

In line with our global guidelines we are supported by our research areas. New discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need.

We build on Boehringer Ingelheim’s strengths in Research & Development by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.

Explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.